Related Experiment Videos
Tr1 cells: from discovery to their clinical application.
Manuela Battaglia1, Silvia Gregori, Rosa Bacchetta
1San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Via Olgettina 58, Milano 20132, Italy.
Seminars in Immunology
|February 9, 2006
Summary
T regulatory type 1 (Tr1) cells suppress immune responses via IL-10 and TGF-beta. Ex vivo generated Tr1 cells show promise for treating T cell-mediated diseases and preventing transplant rejection.
Area of Science:
- Immunology
- Cellular Therapy
- Transplantation Immunology
Background:
- Peripheral tolerance prevents autoimmunity and transplant rejection.
- T regulatory (Tr) cells, including T regulatory type 1 (Tr1) cells, are crucial for immune suppression.
- Tr1 cells produce immunosuppressive cytokines like IL-10 and TGF-beta.
Purpose of the Study:
- To review recent advances in understanding Tr1 cells.
- To discuss methods for ex vivo expansion of Tr1 cells.
- To explore the clinical potential of Tr1 cell therapy.
Main Methods:
- Review of existing literature on Tr1 cell function and therapy.
- Analysis of preclinical data on Tr1 cell efficacy.
- Evaluation of current strategies for ex vivo Tr1 cell generation.
Main Results:
- Tr1 cells effectively down-modulate immune responses.
- Ex vivo generated Tr1 cells have shown efficacy in preclinical models.
- Tr1 cell therapy is a promising approach for various immune-mediated conditions.
Conclusions:
- Tr1 cells are key players in maintaining peripheral tolerance.
- Advancements in ex vivo expansion enhance Tr1 cell therapeutic potential.
- Tr1 cell therapy offers a promising strategy for clinical applications in autoimmunity and transplantation.